Current therapies targeting the Brachyury TF include the BN-brachyury cancer vaccine, which employs a modified vaccinia Ankara (MVA) virus to elicit a robust immune response toward solid tumor cells overexpressing the Brachyury protein (72). The gene discussed is TBX1; the disease is cancer.